Identification of an effective chemotherapy and DNA damage response inhibitor combination for diffuse large b cell lymphoma
- Autori: Chan, A.; Anbuselvan, A.; Upadhyayula, S.S.; Jemimah, S.; Jaynes, P.; Hoppe, M.M.; Wardyn, J.D.; Goh, J.; Bertolazzi, G.; Foiani, M.; O’Connor, M.J.; Chow, E.K.; Tripodo, C.; Jeyasekharan, A.D.
- Anno di pubblicazione: 2022
- Tipologia: Poster pubblicato in rivista
- OA Link: http://hdl.handle.net/10447/581690
Abstract
Chemotherapy forms the backbone of treatment for Diffuse Large B Cell Lymphoma (DLBCL); however, <∼20% of tumors are chemoresistant. Inhibitors of the DNA damage response (DDR) show promise as chemosensitizers. We therefore set up an in-vitro screen to identify an optimal chemotherapy-DDR inhibitor (DDRi) combination in a panel of DLBCL cell lines.